ACC.24 - Daniel Gaudet shares the results of the SHASTA-2 trial. The APOC3 RNAi plozasiran is highly effective and well tolerated in patients with severe hypertriglyceridemia, and demonstrated sustainability in the efficacy through week 48, according to Daniel Gaudet.
More than 70% lowering of triglycerides with APOC3 RNAi in patients with severe hypertriglyceridemia
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
More than 70% lowering of triglycerides with APOC3 RNAi in patients with severe hypertriglyceridemia
Restart
Resume
Transcript
More than 70% lowering of triglycerides with APOC3 RNAi in patients with severe hypertriglyceridemia
closeShare this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Overview
Educational information
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Faculty
Daniel Gaudet, MD, PhD is a clinician-researcher in lipidology and professor of medicine at the Université de Montreal (U de M), in Montreal, QC, Canada.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 9 april 2024
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
ACC.24 - Daniel Gaudet shares the results of the SHASTA-2 trial. The APOC3 RNAi plozasiran is highly effective and well tolerated in patients with severe hypertriglyceridemia, and demonstrated sustainability in the efficacy through week 48, according to Daniel Gaudet.
Educational information
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Faculty
Daniel Gaudet, MD, PhD is a clinician-researcher in lipidology and professor of medicine at the Université de Montreal (U de M), in Montreal, QC, Canada.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 9 april 2024
Presenters
Facebook Comments